


Claims:

1. A composition comprising a compound of Formula (I):



Formula (I)

5 wherein:


- R₁ and R₂ are substituents independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl; C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;
- 10 R₃ is independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; nitro; amino; C₁₋₈alkanylamino, and C₁₋₈dialkanylamino;
- 15 L is a C₁₋₄alkyldiyl optionally substituted with a substituent selected from the group consisting of C₁₋₈alkanyl, C₃₋₈cycloalkanyl and phenyl

optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, and C₁₋₃alkanylamino;

5 R₄ is selected from the group consisting of hydrogen and C₁₋₃alkanyl;
 R₅ is selected from the group consisting of hydrogen and C₁₋₃alkanyl;
 R₆ is selected from the group consisting of phenyl substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, C₃₋₈cycloalkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, 10 fluorinated alkanyl, fluorinated alkanyloxy, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino, aminosulfonyl, C₁₋₈alkanylaminosulfonyl, di(C₁₋₈)alkanylaminosulfonyl and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, 15 halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino, aminosulfonyl, C₁₋₈alkanylaminosulfonyl, di(C₁₋₈)alkanylaminosulfonyl and cyano; heteroaryl optionally substituted with one to two substituents selected from the group consisting of C₁₋₈alkanyl, halogen, 20 C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, and fluorinated alkanyloxy wherein said heteroaryl is thienyl, furanyl, benzthienyl, benzfuranyl, pyridyl, or benzimidazole; C₅₋₇cycloalkanyl optionally substituted with C₁₋₆alkanyl; and cyclic heteroalkanyl selected from the group consisting of morpholinyl, piperazinyl, piperidinyl, imidazolidinyl, pyrazolidinyl, 25 thiomorpholinyl, and pyrrolidinyl;

 X is selected from C-H, N and N->O ;
 Y is C or N, provided that if Y is N then R₃ is absent;
 Z is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically 30 acceptable salts thereof.

2. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

- R_1 and R_2 are substituents independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl; C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; C_{1-7} alkanylaminocarbonyl; C_{1-7} alkanylcarbonylamino; di C_{1-7} alkanylaminocarbonyl; and formyl;
- R_3 is independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; nitro; amino; C_{1-8} alkanylamino, and C_{1-8} dialkanylamino;
- L is a C_{1-4} alkyldiyl optionally substituted with a substituent selected from the group consisting of C_{1-8} alkanyl, C_{3-8} cycloalkanyl and phenyl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyl, halogen, C_{1-8} alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, amino, di(C_{1-3})alkanylamino, and C_{1-3} alkanylamino;


R₄ is selected from the group consisting of hydrogen and C₁₋₃alkanyl;
 R₅ is selected from the group consisting of hydrogen and C₁₋₃alkanyl;
 R₆ is selected from the group consisting of phenyl substituted with one to
 5 three substituents independently selected from the group consisting of
 C₁₋₈alkanyl, C₃₋₈cycloalkanyl, halogen, C₁₋₈alkanyloxy, hydroxy,
 fluorinated alkanyl, fluorinated alkanyloxy, nitro, amino,
 di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino, aminosulfonyl,
 C₁₋₈alkanylaminosulfonyl, di(C₁₋₈)alkanylaminosulfonyl and cyano;
 naphthyl optionally substituted with one to three substituents
 10 independently selected from the group consisting of C₁₋₈alkanyl,
 halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated
 alkanyloxy, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino,
 aminosulfonyl, C₁₋₈alkanylaminosulfonyl, di(C₁₋₈)alkanylaminosulfonyl
 and cyano; heteroaryl optionally substituted with one to two substituents
 15 selected from the group consisting of C₁₋₈alkanyl, halogen,
 C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, and fluorinated alkanyloxy
 wherein said heteroaryl is thienyl, furanyl, benzthienyl, benzfuranyl,
 pyridyl, or benzimidazole; C₅₋₇cycloalkanyl optionally substituted with C₁₋₆
 20 alkanyl; and cyclic heteroalkanyl selected from the group consisting of
 morpholinyl, piperazinyl, piperidinyl, imidazolidinyl, pyrazolidinyl,
 thiomorpholinyl, and pyrrolidinyl;
 X is selected from C-H, N and N->O ;
 Y is C;
 Z is selected from the group consisting of O and S; and
 25 enantiomers, diastereomers, tautomers, solvates, and pharmaceutically
 acceptable salts thereof.

3. The composition of claim 2 wherein R₁ is a substituent
 independently selected from the group consisting of hydrogen; hydroxy;
 30 halogen; and C₁₋₈alkanyl optionally substituted with one or more substituents
 independently selected from the group consisting of halogen, fluorinated
 alkanyl and C₁₋₈alkanyloxy.

4. The composition of claim 2 wherein R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; and C_{1-8} alkanyl.
5. The composition of claim 2 wherein R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; methyl; and chloro.
6. The composition of claim 2 wherein R_2 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; and C_{1-8} alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy.
7. The composition of claim 2 wherein R_2 is hydrogen or halogen.
8. The composition of claim 2 wherein R_2 is hydrogen or chloro.
9. The composition of claim 2 wherein R_3 is independently selected from the group consisting of hydrogen; hydroxy; fluoro; and chloro.
10. The composition of claim 2 wherein R_3 is hydrogen.
11. The composition of claim 2 wherein L is C_{1-4} alkandiyl optionally substituted with a substituent selected from the group consisting of C_{1-8} alkanyl, C_{3-8} cycloalkanyl and phenyl.
12. The composition of claim 2 wherein L is C_{1-4} alkandiyl optionally substituted with a substituent selected from the group consisting of C_{3-8} cycloalkanyl and phenyl.
13. The composition of claim 2 wherein L is $-CH_2-$ and $-CH_2CH_2-$ optionally substituted with a substituent selected from the group consisting of

C₃₋₈cycloalkanyl and phenyl.

14. The composition of claim 2 wherein L is $-\text{CH}_2-$.
- 5 15. The composition of claim 2 wherein R₄ is hydrogen.
16. The composition of claim 2 wherein R₅ is hydrogen.
- 10 17. The composition of claim 2 wherein R₆ is selected from the group consisting of phenyl substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated
15 alkanyloxy; and thienyl optionally substituted with one to two substituents selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy.
- 20 18. The composition of claim 2 wherein R₆ is phenyl substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy.
- 25 19. The composition of claim 2 wherein R₆ is phenyl substituted with one to three substituents independently selected from the group consisting of *t*-butyl, chloro, fluoro, methoxy, trifluoromethyl, and trifluoromethoxy.
- 30 20. The composition of claim 2 wherein Z is O.
21. A compound of Formula (II):



Formula (II)

wherein:

- R_1 and R_2 are substituents independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl; C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; C_{1-7} alkanylaminocarbonyl; C_{1-7} alkanylcarbonylamino; di- C_{1-7} alkanylaminocarbonyl; and formyl;
- R_3 is independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; nitro; amino; C_{1-8} alkanylamino, and C_{1-8} dialkanylamino;
- L is a C_{1-4} alkyldiyl optionally substituted with a substituent selected from the group consisting of C_{1-8} alkanyl, C_{3-8} cycloalkanyl and phenyl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyl, halogen, C_{1-8} alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, amino, di(C_{1-3})alkanylamino, and C_{1-3} alkanylamino;
- R_4 is selected from the group consisting of hydrogen and C_{1-3} alkanyl;
- R_5 is selected from the group consisting of hydrogen and C_{1-3} alkanyl;
- R_6 is selected from the group consisting of phenyl substituted with one to three substituents independently selected from the group consisting of

C₁₋₈alkanyl, C₃₋₈cycloalkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino, aminosulfonyl, C₁₋₈alkanylaminosulfonyl, di(C₁₋₈)alkanylaminosulfonyl and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino, aminosulfonyl, C₁₋₈alkanylaminosulfonyl, di(C₁₋₈)alkanylaminosulfonyl and cyano; heteroaryl optionally substituted with one to two substituents selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, and fluorinated alkanyloxy wherein said heteroaryl is thienyl, furanyl, benzthienyl, benzfuranyl, pyridyl, or benzimidazole; C₅₋₇cycloalkanyl optionally substituted with C₁₋₆alkanyl; and cyclic heteroalkanyl selected from the group consisting of morpholinyl, piperazinyl, piperidinyl, imidazolidinyl, pyrazolidinyl, thiomorpholinyl, and pyrrolidinyl;

X is selected from C-H, N and N->O ;

Y is C or N, provided that if Y is N then R₃ is absent;

Z is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof..

22. The composition of claim 21 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; and C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy.

23. The composition of claim 21 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; and C₁₋₈alkanyl.

24. The composition of claim 21 wherein R₁ is a substituent independently selected from the group^o consisting of hydrogen; hydroxy; methyl; and chloro.

5 25. The composition of claim 21 wherein R₂ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; and C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy.

10 26. The composition of claim 21 wherein R₂ is hydrogen or halogen.

 27. The composition of claim 21 wherein R₂ is hydrogen or chloro.

15 28. The composition of claim 21 wherein L is C₁₋₄alkandiyl optionally substituted with a substituent selected from the group consisting of C₁₋₈alkanyl, C₃₋₈cycloalkanyl and phenyl.

 29. The composition of claim 21 wherein L is C₁₋₄alkandiyl optionally
20 substituted with a substituent selected from the group consisting of
C₃₋₈cycloalkanyl and phenyl.

 30. The composition of claim 21 wherein L is -CH₂- and -CH₂CH₂-
optionally substituted with a substituent selected from the group consisting of
25 C₃₋₈cycloalkanyl and phenyl.

 31. The composition of claim 21 wherein L is -CH₂-.

 32. The composition of claim 21 wherein R₄ is hydrogen.

30 33. The composition of claim 21 wherein R₅ is hydrogen.

 34. The composition of claim 21 wherein R₆ is selected from the group


consisting of phenyl substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy; and thienyl optionally substituted with one to two substituents selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy.

35. The composition of claim 21 wherein R₆ is phenyl substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy.

36. The composition of claim 21 wherein R₆ is phenyl substituted with one to three substituents independently selected from the group consisting of *t*-butyl, chloro, fluoro, methoxy, trifluoromethyl, and trifluoromethoxy.

37. The composition of claim 21 wherein Z is O.

38. A compound of Formula (III):



Formula (III)

wherein:

- 5 R_2 is one to three substituents independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl; C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; C_{1-7} alkanylaminocarbonyl; C_{1-7} alkanylcarbonylamino; diC_{1-7} alkanylaminocarbonyl; and formyl;
- 10 L is C_{1-4} alkyldiyl optionally substituted with a substituent selected from the group consisting of C_{1-8} alkanyl, C_{3-8} cycloalkanyl and phenyl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyl, halogen, C_{1-8} alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, amino, $di(C_{1-3})$ alkanylamino, and C_{1-3} alkanylamino;
- 15 R_4 is selected from the group consisting of hydrogen and C_{1-3} alkanyl;
- 20 R_5 is selected from the group consisting of hydrogen and C_{1-3} alkanyl;
- 25 R_6 is selected from the group consisting of phenyl substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyl, C_{3-8} cycloalkanyl, halogen, C_{1-8} alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, nitro, amino, $di(C_{1-8})$ alkanylamino, C_{1-8} alkanylamino, aminosulfonyl, C_{1-8} alkanylaminosulfonyl, $di(C_{1-8})$ alkanylaminosulfonyl and cyano;
- 30 naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyl, halogen, C_{1-8} alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, nitro, amino, $di(C_{1-8})$ alkanylamino, C_{1-8} alkanylamino,

aminosulfonyl, C₁₋₈alkanylaminosulfonyl, di(C₁₋₈)alkanylaminosulfonyl and cyano; heteroaryl optionally substituted with one to two substituents selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, and fluorinated alkanyloxy
5 wherein said heteroaryl is thienyl, furanyl, benzthienyl, benzfuranyl, pyridyl, or benzimidazole; C₅₋₇cycloalkanyl optionally substituted with C₁₋₆alkanyl; and cyclic heteroalkanyl selected from the group consisting of morpholinyl, piperazinyl, piperidinyl, imidazolidinyl, pyrazolidinyl, thiomorpholinyl, and pyrrolidinyl;
10 Z is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

39. The composition of claim 38 wherein R₁ is a substituent
15 independently selected from the group consisting of hydrogen; hydroxy; halogen; and C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy.

20 40. The composition of claim 38 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; and C₁₋₈alkanyl.

25 41. The composition of claim 38 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; methyl; and chloro.

30 42. The composition of claim 38 wherein R₂ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; and C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy.

43. The composition of claim 38 wherein R_2 is hydrogen or halogen.
44. The composition of claim 38 wherein R_2 is hydrogen or chloro.
- 5 45. The composition of claim 38 wherein L is C_{1-4} alkandiyl optionally substituted with a substituent selected from the group consisting of C_{1-8} alkanyl, C_{3-8} cycloalkanyl and phenyl.
- 10 46. The composition of claim 38 wherein L is C_{1-4} alkandiyl optionally substituted with a substituent selected from the group consisting of C_{3-8} cycloalkanyl and phenyl.
- 15 47. The composition of claim 38 wherein L is $-CH_2-$ and $-CH_2CH_2-$ optionally substituted with a substituent selected from the group consisting of C_{3-8} cycloalkanyl and phenyl.
48. The composition of claim 38 wherein L is $-CH_2-$.
49. The composition of claim 38 wherein R_4 is hydrogen.
- 20 50. The composition of claim 38 wherein R_5 is hydrogen.
- 25 51. The composition of claim 38 wherein R_6 is selected from the group consisting of phenyl substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyl, chloro, fluoro, C_{1-8} alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyl, chloro, fluoro, C_{1-8} alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy; and thieryl optionally substituted with one to two substituents selected from the group consisting of C_{1-8} alkanyl, chloro, fluoro, C_{1-8} alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy.
- 30 52. The composition of claim 38 wherein R_6 is phenyl substituted with


one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy.

5 53. The composition of claim 38 wherein R₆ is phenyl substituted with one to three substituents independently selected from the group consisting of *t*-butyl, chloro, fluoro, methoxy, trifluoromethyl, and trifluoromethoxy.

54. The composition of claim 38 wherein Z is O.

10

55. A composition comprising a compound of Formula (IV):



Formula (IV)

wherein:

15 R₁ and R₂ are substituents independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino;

20

- C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl; C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;
- 5 R₃ is independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; nitro; amino; C₁₋₈alkanylamino, and C₁₋₈dialkanylamino;
- 10 L is C₁₋₄alkyldiyl optionally substituted with a substituent selected from the group consisting of C₁₋₈alkanyl, C₃₋₈cycloalkanyl and phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, and C₁₋₃alkanylamino;
- 15 R₄ is selected from the group consisting of hydrogen and C₁₋₃alkanyl;
- 15 R₅ is selected from the group consisting of hydrogen and C₁₋₃alkanyl;
- 20 R₆ is selected from the group consisting of phenyl substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, C₃₋₈cycloalkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino, aminosulfonyl, C₁₋₈alkanylaminosulfonyl, di(C₁₋₈)alkanylaminosulfonyl and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino, aminosulfonyl, C₁₋₈alkanylaminosulfonyl, di(C₁₋₈)alkanylaminosulfonyl and cyano; heteroaryl optionally substituted with one to two substituents selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, and fluorinated alkanyloxy
- 25 wherein said heteroaryl is thienyl, furanyl, benzthienyl, benzfuranyl, pyridyl, or benzimidazole; C₅₋₇cycloalkanyl optionally substituted with C₁₋₆alkanyl; and cyclic heteroalkanyl selected from the group consisting of morpholiny, piperaziny, piperidiny, imidazolidiny, pyrazolidiny,
- 30

thiomorpholinyl, and pyrrolidinyl;

Z is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

5

56. The composition of claim 55 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; and C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy.

10

57. The composition of claim 55 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; and C₁₋₈alkanyl.

15

58. The composition of claim 55 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; methyl; and chloro.

20

59. The composition of claim 55 wherein R₂ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; and C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy.

25

60. The composition of claim 55 wherein R₂ is hydrogen or halogen.

61. The composition of claim 55 wherein R₂ is hydrogen or chloro.

30

62. The composition of claim 55 wherein L is C₁₋₄alkandiyl optionally substituted with a substituent selected from the group consisting of C₁₋₈alkanyl, C₃₋₈cycloalkanyl and phenyl.

63. The composition of claim 55 wherein L is C₁₋₄alkandiyl optionally substituted with a substituent selected from the group consisting of C₃₋₈cycloalkanyl and phenyl.
- 5 64. The composition of claim 55 wherein L is –CH₂– and –CH₂CH₂– optionally substituted with a substituent selected from the group consisting of C₃₋₈cycloalkanyl and phenyl.
- 10 65. The composition of claim 55 wherein L is –CH₂–.
66. The composition of claim 55 wherein R₄ is hydrogen.
67. The composition of claim 55 wherein R₅ is hydrogen.
- 15 68. The composition of claim 55 wherein R₆ is selected from the group consisting of phenyl substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy; and thienyl optionally substituted with one to two substituents selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy.
- 20 69. The composition of claim 55 wherein R₆ is phenyl substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, chloro, fluoro, C₁₋₈alkanyloxy, fluorinated alkanyl, and fluorinated alkanyloxy.
- 25 70. The composition of claim 55 wherein R₆ is phenyl substituted with one to three substituents independently selected from the group consisting of *t*-butyl, chloro, fluoro, methoxy, trifluoromethyl, and trifluoromethoxy.
- 30


71. The composition of claim 55 wherein Z is O.

72. The composition of claim 2 wherein R₃ is independently selected from the group consisting of hydrogen; hydroxy; fluoro; and chloro.

5

73. The composition of claim 2 wherein R₃ is hydrogen.

74. A composition comprising a compound of Formula (V):



Formula (V)

10

wherein:

15

20

25

R₁ and R₂ are substituents independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl; C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;

R₃ is independently selected from the group consisting of hydrogen; hydroxy; fluoro; and chloro; nitro; amino; C₁₋₈alkanylamino, and C₁₋₈dialkanylamino;

L is C₁₋₄alkyldiyl optionally substituted with a substituent selected from the

group consisting of C₁₋₈alkanyl, C₃₋₈cycloalkanyl and phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, and C₁₋₃alkanylamino;

5 R₄ is selected from the group consisting of hydrogen and C₁₋₃alkanyl;
 R₅ is selected from the group consisting of hydrogen and C₁₋₃alkanyl;
 R₆ is selected from the group consisting of phenyl substituted with one to three substituents independently selected from the group consisting of

10 C₁₋₈alkanyl, C₃₋₈cycloalkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino, aminosulfonyl, C₁₋₈alkanylaminosulfonyl, di(C₁₋₈)alkanylaminosulfonyl and cyano; naphthyl optionally substituted with one to three substituents

15 independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino, aminosulfonyl, C₁₋₈alkanylaminosulfonyl, di(C₁₋₈)alkanylaminosulfonyl and cyano; heteroaryl optionally substituted with one to two substituents

20 selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, and fluorinated alkanyloxy wherein said heteroaryl is thienyl, furanyl, benzthienyl, benzfuranyl, pyridyl, or benzimidazole; C₅₋₇cycloalkanyl optionally substituted with C₁₋₆alkanyl; and cyclic heteroalkanyl selected from the group consisting of

25 morpholinyl, piperazinyl, piperidinyl, imidazolidinyl, pyrazolidinyl, thiomorpholinyl, and pyrrolidinyl;

 X is N or N->O ;

 Z is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically


30 acceptable salts thereof.

75. The composition according to claim 74 wherein X is N, R₁ is hydroxy, and R₃ is hydrogen.

76. The composition according to claim 74 wherein X is N, R₁ is hydroxy; R₂, R₃, R₄, and R₅ are hydrogen; R₆ is 3,4-di-substituted phenyl, and Z is O.

77. The composition according to claim 74 wherein X is N, R₁ is hydroxy, R₂, R₃, R₄, and R₅ are hydrogen; R₆ is 3-trifluoromethyl-4-chlorophenyl, and Z is O.

78. A composition comprising a compound of Formula (Ia):



Formula (Ia)

wherein the compound is selected from the group consisting of:

a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂CH₂-, R₆ is (3,4-diCl)Ph, X is N, and Y is C;

a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂CH₂-, R₆ is (3-CF₃)Ph, X is N, and Y is C;

a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂CH₂-, R₆ is (4-Cl)Ph, X is N, and Y is C;

a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (4-CF₃)Ph, X is N, and Y is C;

a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (3,4-diCl)Ph, X is N, and Y is C;

- a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (4-Cl)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (3- CF_3)Ph, X is N, and Y is C;
- 5 a compound of formula (Ia) wherein R_1 is Me, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (3,4-diCl)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R_1 is Me, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (3- CF_3)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2\text{CH}((4\text{-OMe})\text{Ph})-$, R_6 is Pyridin-3-yl, X is N, and Y is C;
- 10 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2\text{CH}(-\text{CH}_2\text{Ph})-$, R_6 is (4-OMe)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2\text{CH}(-\text{CH}_2\text{cyclohexyl})-$, R_6 is (4-OMe)Ph, X is N, and Y is C;
- 15 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (4-*t*-Bu)Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (4-Cl)Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is Pyridin-3-yl, X is C and Y is C;
- 20 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (4-OCF₃)Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (4- CF_3)Ph, X is C and Y is C;
- 25 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (3- CF_3)Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (3- CF_3 -4-Cl)Ph, X is N, and Y is C;
- 30 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2\text{CH}_2-$, R_6 is (4-OMe)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L

- is -CH₂-, R₆ is (4-OCF₃)Ph, X is N, and Y is C;
a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
L is -CH₂CH₂-, R₆ is Ph, X is C and Y is C;
a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is Et,
5 L is -CH₂-, R₆ is Ph, X is C and Y is C;
a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is
Benzyl, L is -CH₂-, R₆ is Ph, X is C and Y is C;
a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is
Me, L is -CH₂-, R₆ is Ph, X is C and Y is C;
10 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
L is -CH₂CH₂-, R₆ is (3,4-diCl)Ph, X is C and Y is C;
a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is
-CH₂CH₂PH, L is -CH₂-, R₆ is Ph, X is C and Y is C;
a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
15 L is -CH₂-, R₆ is (6-CF₃)Pyridin-3-yl, X is C and Y is C;
a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is
Me, L is -CH₂-, R₆ is (3,4-diCl)Ph, X is C and Y is C;
a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
L is -CH₂-, R₆ is (3,4-diCl)Ph, X is C and Y is C;
20 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
L is -CH₂-, R₆ is Benzimidazol-2-yl, X is C and Y is C;
a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L
is -CH₂-, R₆ is (4-*t*-Bu)Ph, X is N, and Y is C;
a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L
25 is -CH₂CH₂-, R₆ is Ph, X is N, and Y is C;
a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L
is -CH₂CH₂-, R₆ is (4-*t*-Bu)Ph, X is N, and Y is C;
a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L
is -CH₂CH₂-, R₆ is (4-CF₃)Ph, X is N, and Y is C;
30 a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L
is -CH₂-, R₆ is (4-OMe)Ph, X is N, and Y is C;
a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L
is -CH₂CH₂-, R₆ is (4-OCF₃)Ph, X is N, and Y is C;

- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2-$, R_6 is (5-thiophen-2-yl)Thiophen-2-yl, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2-$, R_6 is Benzthiophen-2-yl, X is C and Y is C;
- 5 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2-$, R_6 is (2-Br)Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2-$, R_6 is (3,4-diF)Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
10 L is $-\text{CH}_2-$, R_6 is (5-Cl)Benzthiophen-3-yl, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2\text{CH}_2-$, R_6 is (2-Cl)Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2-$, R_6 is (2,6-diCl)Ph, X is C and Y is C;
- 15 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2\text{CH}_2-$, R_6 is (4- SO_2NH_2)Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2-$, R_6 is (2,4-diCl)Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
20 L is $-\text{CH}_2-$, R_6 is (5-Pyridin-2-yl)Thiophene-2-yl, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2-$, R_6 is Pyridin-2-yl, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2\text{CH}(\text{Ph})-$, R_6 is Ph, X is C and Y is C;
- 25 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2\text{CH}_2\text{CH}_2-$, R_6 is Morpholin-1-yl, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2-$, R_6 is 6,6-DiMe,thyl-bicyclo[3.1.1]heptan-2-yl, X is C and Y is
C;
- 30 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2-$, R_6 is Cyclohexyl, X is C and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
L is $-\text{CH}_2\text{CH}_2-$, R_6 is Pyridin-2-yl, X is C and Y is C;

- a compound of formula (Ia) wherein R₁ is H, R₂ is Cl, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (4-CF₃)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (3-CF₃-4-F)Ph, X is C and Y is C;
- 5 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (3-CF₃-4-Cl)Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (3,5-diCF₃)Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is Cl, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (4-CF₃)Ph, X is N, and Y is C;
- 10 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH(Me)-, R₆ is (3-CF₃-4-Cl)Ph, X is C and Y is C;
- a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH(Ph)CH₂-, R₆ is Ph, X is C and Y is C; and
- 15 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (2,4-diCl)Ph, X is C and Y is C.

79. A composition according to claim 78 wherein the compound is selected from the group consisting of:
- 20 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (4-CF₃)Ph, X is C, and Y is C;
- a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (4-OCF₃)Ph, X is C, and Y is C;
- a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (4-*t*-Bu)Ph, X is C, and Y is C;
- 25 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (3-CF₃)Ph, X is C, and Y is C;
- a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (3-CF₃-4-Cl)Ph, X is C, and Y is C;
- 30 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂CH₂-, R₆ is (3,4-diCl)Ph, X is C, and Y is C;
- a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (3,4-diCl)Ph, X is C, and Y is C;

- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (2,4-diCl)Ph, X is C, and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (4-Cl)Ph, X is C, and Y is C;
- 5 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (3,5-diCF₃)Ph, X is C, and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (3,4-diF)Ph, X is C, and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (6-CF₃)Pyridin-3-yl, X is C, and Y is C;
- 10 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2\text{CH}_2-$, R_6 is Ph, X is C, and Y is C;
- a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is Ph, X is C, and Y is C;
- 15 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (4-*t*-Bu)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (3-CF₃-4-Cl)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (4-OCF₃)Ph, X is N, and Y is C;
- 20 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2\text{CH}_2-$, R_6 is (4-*t*-Bu)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2\text{CH}(-\text{CH}_2\text{cyclohexyl})-$, R_6 is (4-OMe)Ph, X is N, and Y is C;
- 25 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2\text{CH}(-\text{CH}_2\text{Ph})-$, R_6 is (4-OMe)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2\text{CH}_2-$, R_6 is (4-OCF₃)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (4-CF₃)Ph, X is N, and Y is C;
- 30 a compound of formula (Ia) wherein R_1 is H, R_2 is Cl, R_3 is H, R_4 is H, R_5 is H, L is $-\text{CH}_2-$, R_6 is (4-CF₃)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L

- is -CH₂-, R₆ is (3,4-diCl)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L
 is -CH₂CH₂-, R₆ is (3,4-diCl)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R₁ is Me, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
 5 L is -CH₂-, R₆ is (3,4-diCl)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L
 is -CH₂CH₂-, R₆ is (4-CF₃)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L
 is -CH₂-, R₆ is (3-CF₃)Ph, X is N, and Y is C;
 10 a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L
 is -CH₂-, R₆ is (4-Cl)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R₁ is Me, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
 L is -CH₂-, R₆ is (3-CF₃)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L
 15 is -CH₂CH₂-, R₆ is (3-CF₃)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
 L is -CH₂CH₂-, R₆ is (4-Cl)Ph, X is N, and Y is C; and
 a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
 L is -CH₂-, R₆ is (4-OMe)Ph, X is N, and Y is C.

20


80. A composition according to claim 78 wherein the compound is
 selected from the group consisting of:
 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
 L is -CH₂-, R₆ is (4-CF₃)Ph, X is C, and Y is C;
 25 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
 L is -CH₂-, R₆ is (4-OCF₃)Ph, X is C, and Y is C;
 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
 L is -CH₂-, R₆ is (4-*t*-Bu)Ph, X is C, and Y is C;
 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
 30 L is -CH₂-, R₆ is (3-CF₃)Ph, X is C, and Y is C;
 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H,
 L is -CH₂-, R₆ is (3-CF₃-4-Cl)Ph, X is C, and Y is C;
 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H,

- L is $-\text{CH}_2\text{CH}_2-$, R_6 is (3,4-diCl)Ph, X is C, and Y is C;
 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
 L is $-\text{CH}_2-$, R_6 is (3,4-diCl)Ph, X is C, and Y is C;
 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
 5 L is $-\text{CH}_2-$, R_6 is (2,4-diCl)Ph, X is C, and Y is C;
 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
 L is $-\text{CH}_2-$, R_6 is (4-Cl)Ph, X is C, and Y is C;
 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
 L is $-\text{CH}_2-$, R_6 is (3,5-diCF₃)Ph, X is C, and Y is C;
 10 a compound of formula (Ia) wherein R_1 is OH, R_2 is H, R_3 is H, R_4 is H, R_5 is H,
 L is $-\text{CH}_2-$, R_6 is (3,4-diF)Ph, X is C, and Y is C;
 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L
 is $-\text{CH}_2-$, R_6 is (4-*t*-Bu)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L
 15 is $-\text{CH}_2-$, R_6 is (3-CF₃-4-Cl)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L
 is $-\text{CH}_2-$, R_6 is (4-OCF₃)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L
 is $-\text{CH}_2\text{CH}_2-$, R_6 is (4-*t*-Bu)Ph, X is N, and Y is C;
 20 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L
 is $-\text{CH}_2\text{CH}(-\text{CH}_2\text{cyclohexyl})-$, R_6 is (4-OMe)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L
 is $-\text{CH}_2\text{CH}(-\text{CH}_2\text{Ph})-$, R_6 is (4-OMe)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L
 25 is $-\text{CH}_2\text{CH}_2-$, R_6 is (4-OCF₃)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L
 is $-\text{CH}_2-$, R_6 is (4-CF₃)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R_1 is H, R_2 is Cl, R_3 is H, R_4 is H, R_5 is H, L
 is $-\text{CH}_2-$, R_6 is (4-CF₃)Ph, X is N, and Y is C;
 30 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L
 is $-\text{CH}_2-$, R_6 is (3,4-diCl)Ph, X is N, and Y is C;
 a compound of formula (Ia) wherein R_1 is H, R_2 is H, R_3 is H, R_4 is H, R_5 is H, L
 is $-\text{CH}_2\text{CH}_2-$, R_6 is (3,4-diCl)Ph, X is N, and Y is C; and

a compound of formula (Ia) wherein R₁ is Me, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (3,4-diCl)Ph, X is N, and Y is C.

81. A composition according to claim 78 wherein the compound is
- 5 selected from the group consisting of:
- a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (4-CF₃)Ph, X is C, and Y is C;
- a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (4-OCF₃)Ph, X is C, and Y is C;
- 10 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (4-*t*-Bu)Ph, X is C, and Y is C;
- a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (3-CF₃)Ph, X is C, and Y is C;
- a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (3-CF₃-4-Cl)Ph, X is C, and Y is C;
- 15 a compound of formula (Ia) wherein R₁ is OH, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂CH₂-, R₆ is (3,4-diCl)Ph, X is C, and Y is C;
- a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (4-*t*-Bu)Ph, X is N, and Y is C;
- 20 a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (3-CF₃-4-Cl)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R₁ is Me, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (4-CF₃)Ph, X is N, and Y is C;
- a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂-, R₆ is (4-OCF₃)Ph, X is N, and Y is C; and
- 25 a compound of formula (Ia) wherein R₁ is H, R₂ is H, R₃ is H, R₄ is H, R₅ is H, L is -CH₂CH₂-, R₆ is (4-*t*-Bu)Ph, X is N, and Y is C.

82. A composition comprising a compound of Formula (II):



Formula (II)

wherein the compound is selected from the group consisting of:

- a compound of formula (II) wherein R₁ is H, R₂ is H, R₄ is H, R₅ is H, L is R₆ is
5 (3-CF₃)Ph, and Z is O;
a compound of formula (II) wherein R₁ is H, R₂ is H, R₄ is H, R₅ is H, L is -CH₂-,
R₆ is (4-CF₃)Ph, and Z is O;
a compound of formula (II) wherein R₁ is H, R₂ is H, R₄ is H, R₅ is H, L is -CH₂-,
R₆ is (3,4-diCl)Ph, and Z is O;
10 a compound of formula (II) wherein R₁ is H, R₂ is H, R₄ is H, R₅ is H, L is -
CH₂CH₂-, R₆ is (3,4-diCl)Ph, and Z is O;
a compound of formula (II) wherein R₁ is H, R₂ is H, R₄ is H, R₅ is H, L is -CH₂-,
R₆ is (4-N(Me)*n*-pentyl)Ph, and Z is O; and
a compound of formula (II) wherein R₁ is H, R₂ is H, R₄ is H, R₅ is H, L is -CH₂-,
15 R₆ is (4-N(Me)CH₂cyclohexyl)Ph, and Z is O.

83. A pharmaceutical composition comprising a compound, salt or
solvate according to claim 2 admixed with a pharmaceutically acceptable
carrier, excipient or diluent.

20

84. A veterinary composition comprising a compound, salt or solvate
according to claim 2 admixed with a veterinarily acceptable carrier, excipient or
dilluent.

25 85. A method of treating or preventing a disease or condition in a
mammal which disease or condition is affected by the modulation of one or
more vanilloid receptors, which method comprises administering to a mammal
in need of such treatment or prevention a therapeutically effective amount of a
compound, salt or solvate of claim 2.

86. A method for preventing or treating a chronic-pain causing disease or condition, an acute-pain causing disease or condition, or a pulmonary dysfunction comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of claim 2.

87. A method for preventing or treating a disease or condition, wherein said disease or condition causes inflammatory pain, burning pain, itch urinary incontinence, or chronic obstructive pulmonary disease, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of claim 2.

88. A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, inflammatory bowel diseases such as Crohn's Disease and ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's

neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstruation, hot flash, cancer, and trauma, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of claim 2.

89. The method of claim 88 wherein said therapeutically effective amount comprises a dose range of from about 0.001 mg to about 1,000 mg.

10

90. The method of claim 88 wherein said therapeutically effective amount comprises a dose range of from about 0.1 mg to about 500 mg.

91. The method of claim 88 wherein said therapeutically effective amount comprises a dose range of from about 1 mg to about 250 mg.

15

92. A kit comprising in one or more containers an amount of the composition of claim 2 effective to treat or prevent a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, inflammatory bowel diseases such as Crohn's Disease and ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia,

35

idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas,
5 menstruation, hot flash, cancer, and trauma.

93. A pharmaceutical composition comprising a compound, salt or solvate according to claim 21 admixed with a pharmaceutically acceptable carrier, excipient or diluent.

10

94. A veterinary composition comprising a compound, salt or solvate according to claim 21 admixed with a veterinarily acceptable carrier, excipient or diluent.

15 95. A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough,
20 asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis,
25 polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, inflammatory bowel diseases such as Crohn's Disease and ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome,
30 optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's

neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstruation, hot flash, cancer, and trauma, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of claim 21.

96. The method of claim 95 wherein said therapeutically effective amount comprises a dose range of from about 0.001 mg to about 1,000 mg.

97. The method of claim 95 wherein said therapeutically effective amount comprises a dose range of from about 0.1 mg to about 500 mg.

98. The method of claim 95 wherein said therapeutically effective amount comprises a dose range of from about 1 mg to about 250 mg.

99. A kit comprising in one or more containers an amount of the composition of claim 21 effective to treat or prevent a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, inflammatory bowel diseases such as Crohn's Disease and ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia,

geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, 5 sinus headache, tension headache, labor, childbirth, intestinal gas, menstruation, hot flash, cancer, and trauma.

100. A pharmaceutical composition comprising a compound, salt or solvate according to claim 38 admixed with a pharmaceutically acceptable 10 carrier, excipient or diluent.

101. A veterinary composition comprising a compound, salt or solvate according to claim 38 admixed with a veterinarily acceptable carrier, excipient or dilluent.

15

102. A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, 20 benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, 25 causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, inflammatory bowel diseases such as Crohn's Disease and ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, 30 Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia,

idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas,

- 5 menstruation, hot flash, cancer, and trauma, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of claim 38.

10 103. The method of claim 102 wherein said therapeutically effective amount comprises a dose range of from about 0.001 mg to about 1,000 mg.

104. The method of claim 102 wherein said therapeutically effective amount comprises a dose range of from about 0.1 mg to about 500 mg.

15 105. The method of claim 102 wherein said therapeutically effective amount comprises a dose range of from about 1 mg to about 250 mg.

20 106. A kit comprising in one or more containers an amount of the composition of claim 38 effective to treat or prevent a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact
25 dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative
30 ileus, irritable bowel syndrome, inflammatory bowel diseases such as Crohn's Disease and ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis,
35 Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia,

geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, 5 sinus headache, tension headache, labor, childbirth, intestinal gas, menstruation, hot flash, cancer, and trauma.

107. A pharmaceutical composition comprising a compound, salt or solvate according to claim 55 admixed with a pharmaceutically acceptable 10 carrier, excipient or diluent.

108. A veterinary composition comprising a compound, salt or solvate according to claim 55 admixed with a veterinarily acceptable carrier, excipient or dilluent. 15

109. A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, 20 benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, 25 causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, inflammatory bowel diseases such as Crohn's Disease and ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, 30 Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's

neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstruation, hot flash, cancer, and trauma, said method comprising the step
5 of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of claim 55.

110. The method of claim 109 wherein said therapeutically effective amount comprises a dose range of from about 0.001 mg to about 1,000 mg.
10

111. The method of claim 109 wherein said therapeutically effective amount comprises a dose range of from about 0.1 mg to about 500 mg.

112. The method of claim 109 wherein said therapeutically effective
15 amount comprises a dose range of from about 1 mg to about 250 mg.

113. A kit comprising in one or more containers an amount of the composition of claim 55 effective to treat or prevent a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis,
20 fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, pharyngitis,
25 mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, inflammatory bowel diseases such as Crohn's
30 Disease and ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia,
35 geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia,

idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas,
5 menstruation, hot flash, cancer, and trauma.

114. A pharmaceutical composition comprising a compound, salt or solvate according to claim 74 admixed with a pharmaceutically acceptable carrier, excipient or diluent.

10

115. A veterinary composition comprising a compound, salt or solvate according to claim 74 admixed with a veterinarily acceptable carrier, excipient or dilluent.

116. A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough,
15 asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis,
20 polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, inflammatory bowel diseases such as Crohn's Disease and ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome,
25 optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's

30

neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstruation, hot flash, cancer, and trauma, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of claim 74.

117. The method of claim 116 wherein said therapeutically effective amount comprises a dose range of from about 0.001 mg to about 1,000 mg.

118. The method of claim 116 wherein said therapeutically effective amount comprises a dose range of from about 0.1 mg to about 500 mg.

119. The method of claim 116 wherein said therapeutically effective amount comprises a dose range of from about 1 mg to about 250 mg.

120. A kit comprising in one or more containers an amount of the composition of claim 74 effective to treat or prevent a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, inflammatory bowel diseases such as Crohn's Disease and ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's

neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstruation, hot flash, cancer, and trauma.

5